Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (321-330 of 574) with videos related to

Pageof 58
Sort By:
Clinical Lung Cancer|February 14, 2021
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint InhibitorsSally C M Lau, Aline Fusco Fares, Lisa W Le, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
Taletrectinib in <i>ROS1</i>+ Non-Small Cell Lung Cancer: TRUSTMaurice Pérol, Wei Li, Nathan A Pennell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancerLinda E Coate, Christine Massey, Andrew Hope, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
The Oncologist|April 3, 2019
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric CancerAnuradha Vasista, Martin Stockler, Andrew Martin, et al.
Iscience|November 25, 2022
Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtractionSami Ul Haq, Sabine Schmid, Mansi K Aparnathi, et al.
International Journal of Cancer|September 16, 2021
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
Heliyon|September 19, 2024
Outcomes with non-small cell lung cancer and brain-only metastasisSabine Schmid, Miguel Garcia, Luna Zhan, et al.
International Journal of Cardiology|May 1, 2018
Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trialsRobert Avram, Guillaume Marquis-Gravel, François Simard, et al.
Pageof 58

Showing results (321-330 of 574) with videos related to

Sort By:
Pageof 58
Clinical Lung Cancer|February 14, 2021
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint InhibitorsSally C M Lau, Aline Fusco Fares, Lisa W Le, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsPooja Middha, Rohit Thummalapalli, Zoe Quandt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
Taletrectinib in <i>ROS1</i>+ Non-Small Cell Lung Cancer: TRUSTMaurice Pérol, Wei Li, Nathan A Pennell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancerLinda E Coate, Christine Massey, Andrew Hope, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
The Oncologist|April 3, 2019
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric CancerAnuradha Vasista, Martin Stockler, Andrew Martin, et al.
Iscience|November 25, 2022
Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtractionSami Ul Haq, Sabine Schmid, Mansi K Aparnathi, et al.
International Journal of Cancer|September 16, 2021
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
Heliyon|September 19, 2024
Outcomes with non-small cell lung cancer and brain-only metastasisSabine Schmid, Miguel Garcia, Luna Zhan, et al.
International Journal of Cardiology|May 1, 2018
Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trialsRobert Avram, Guillaume Marquis-Gravel, François Simard, et al.
Pageof 58